ArticleTranslational oncology2025
Personalizing colorectal Cancer treatment: Chemotherapy drug testing with patient-derived tumor cell clusters.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ex vivo organotypic culture of liposarcoma effectively models in vivo supratherapeutic paclitaxel localized drug delivery.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the heterogeneity of colorectal cancer (CRC), models that can predict the chemotherapy response are needed to facilitate personalized treatment.
aimTo construct patient-derived tumor-like cell cluster (PTC) models in vitro drug sensitivity screening for CRC personalized chemotherapy.
methodsWe collected 140 CRC tissues via surgical resection in three Chinese hospitals and establish PTC models which is highly similar to the original tumor tissue. The sensitivity to various chemotherapy drugs was assessed in these PTC models. We recorded the PTC model cultivation process and patients' clinical data and assessed the concordance between in vitro drug sensitivity and clinical outcomes.
resultsPTC models were successfully established from 124 specimens, with a success rate of 88.6 %. The average culture time was 3.02 ± 1.56 days, and the median time to obtain drug sensitivity results was 11 days (10-13 days). Drug sensitivity testing revealed that the PTC models had variable responses to different chemotherapy regimens, with some patients showing unexpected sensitivity to regimens not typically considered first-line treatments. The median follow-up time for all patients was 19 months, and there was no significant difference in disease-free survival (DFS) between patients whose actual responses to clinical treatment regimens were consistent or inconsistent with the PTC model predictions.
conclusionThe PTC model for drug sensitivity testing has advantages of high success rate and rapid drug screening time. This study provides a promising tool for personalized chemotherapy sensitivity screening in patients with CRC and, after further clinical trials, may guide clinical treatment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.